Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > A lot of divirsity of opinions here

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Jul 26, 2021 10:36am

75 Views

Post# 33604102

RE:RE:RE:RE:RE:RE:RE:RE:RE:A lot of divirsity of opinions here

ATM as lubrication ........... or it's just cash $tupid???

qwerty22 wrote:

It seems to me there's a price to be paid for everything.

Wouldn't there be some usefulness in getting steady pickup in volume in advance of the cancer news. If some Cantor clients heard something they liked last week and do further research then having an avenue for these guys to buy might just be the lubricant needed for the rest of the market.

This board have identified in the past a whole bunch of factors suppressing the SP (low new institutional interest, low vol, low analyst coverage, low market cap). All these things seem to act as positive feedbacks suppressing each other. Is there a need to break that cycle and get things moving.

I think PoC is massive for them but it's still very early data and so it's still high risk for anybody wanting to take long term positions. A bit of lubrication might still be needed. Can the ATM do that? I'm thinking getting some of these shares sold before the news might help, as I said that's the price you pay???

palinc2000 wrote: If my interpretation is correct and they hold off till September 1 st before drawing on the ATM then we wont find out untill mid to end of February if any stock was issued in the current FY,,,
but I guess Scarlett might be able to detect such sales just by spotting unusual trades

palinc2000 wrote: I interpret the filing period to be when the Quarterly Results are filed,,,The 3 rd ends on August 31 and they will report around mid October,,,,If they dont want to spook the market they should wait at least till Sept 1 before issuing any stock which would be reported in February 2022 only

palinc2000 wrote:

The Corporation will disclose the number and average price of the Common Shares sold under this Prospectus Supplement, as well as the gross proceeds, Agent’s Fees and net proceeds from sales hereunder in the Corporation’s public disclosure documents filed on SEDAR and EDGAR, for any periods in which sales of Common Shares occur. The Corporation or the Agent may suspend the offering of Common Shares upon proper notice and subject to the terms and conditions set forth in the Sales Agreement. A copy of the Sales Agreement is available electronically under the Corporation’s profile at www.sedar.com and on the SEC’s website at www.sec.gov.